Dyax Corp. (NASDAQ: DYAX) said the FDA'S Pulmonary-Allergy Drugs Advisory Committee is scheduled to discuss the Company's Biologics License Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE